PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1454083
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1454083
According to Stratistics MRC, the Global Red Yeast Rice Market is accounted for $1.1 billion in 2023 and is expected to reach $2.4 billion by 2030 growing at a CAGR of 12.4% during the forecast period. Red Yeast Rice (RYR) is a traditional Chinese culinary and medicinal product made by fermenting rice with the Monascus purpureus mold. It contains naturally occurring compounds known as monacolins, with monacolin K being identical to lovastatin, a cholesterol-lowering medication. RYR has been used for centuries in traditional Chinese medicine to promote cardiovascular health. Its active compounds are believed to inhibit cholesterol synthesis and lower LDL ("bad") cholesterol levels. Some people use RYR as a natural alternative for managing cholesterol levels.
Rising awareness of natural cholesterol-lowering solutions
As consumers become more health-conscious and seek alternatives to synthetic medications, red yeast rice, known for its potential to lower cholesterol levels, has gained popularity. The rising awareness of the adverse effects associated with conventional cholesterol-lowering drugs has driven individuals toward natural remedies. Consumers are actively seeking products like red yeast rice that offer a natural approach to managing cholesterol without compromising overall health. Thus, the demand for red yeast rice has surged as people recognize its historical use in traditional medicine and its alignment with the broader trend of embracing natural, plant-based solutions for health and wellness.
Safety concerns and potential side effects
Safety concerns surrounding red yeast rice cast a shadow over the market. Unlike strictly regulated prescription drugs, red yeast rice can cause muscle aches, digestive issues, and interact with other medications. These potential side effects raise red flags for both consumers and healthcare professionals. Consumers wary of unintended consequences may opt for established medications. Further doctors, prioritizing patient safety, might hesitate to recommend red yeast rice due to the lack of long-term data and potential interactions with current medications.
Growing prevalence of cardiovascular diseases
Cardiovascular health concerns escalate globally; there is an increased demand for natural solutions that can contribute to cholesterol management, a key factor in cardiovascular health. Red yeast rice, containing compounds like monacolins, which may help lower cholesterol levels, has gained attention as a potential preventive measure against heart-related issues. The rise in CVD cases has prompted individuals to seek proactive approaches to manage heart health, driving the adoption of red yeast rice supplements contributing to the market growth.
Competition from established cholesterol-lowering drugs
The dominance of established cholesterol-lowering medications throws a significant hurdle at the red yeast rice market. These prescription drugs boast a long history of proven effectiveness, extensive clinical research, and the trust of doctors. This makes them the go-to option for many healthcare providers, hindering red yeast rice's integration into mainstream cholesterol management. Furthermore, established drugs may be covered by insurance, making them a more cost-effective choice for some patients compared to out-of-pocket expenses for red yeast rice.
Covid-19 Impact
The COVID-19 pandemic impacted the red yeast rice market in two key ways. Firstly, the focus shifted towards immediate health concerns. People prioritized treating and preventing COVID-1chronic health conditions like high cholesterol took a backseat. This led to a decline in demand for supplements like red yeast rice. This made it difficult for manufacturers to source ingredients and distributors to deliver the product, hindering overall market activity. While the market is expected to recover as people resume focusing on preventative healthcare, the pandemic's effects are likely to be felt for some time.
The powder segment is expected to be the largest during the forecast period
The powder segment is estimated to have a lucrative growth, owing to ease of incorporation into various food and beverage products, expanding its usage beyond traditional supplements. This innovation caters to consumer preferences for convenient and customizable consumption, driving demand and market growth. Additionally, powdered Red Yeast Rice often retains its nutritional benefits, maintaining its cholesterol-lowering properties encourage the market growth.
The dietary supplements segment is expected to have the highest CAGR during the forecast period
The dietary supplements segment is anticipated to witness the highest CAGR growth during the forecast period, due to widely recognized for its potential cholesterol-lowering benefits, it has become a sought-after ingredient in cardiovascular health supplements. The incorporation of Red Yeast Rice into dietary supplements has expanded its consumer reach, offering individuals a convenient and standardized way to incorporate its health benefits into their daily routines. The demand for combination supplements, blending Red Yeast Rice with other heart-healthy ingredients, has further amplified its market presence.
Asia Pacific is projected to hold the largest market share during the forecast period because red yeast rice has been traditionally used in Asian cuisines for its distinctive flavor and color. It is often used to impart a reddish hue to food, as well as for its subtle sweet taste. Moreover, red yeast rice has gained popularity for its potential health benefits, particularly in managing cholesterol levels. Some studies suggest that the monacolin K in red yeast rice may help a lower LDL cholesterol level which boosts the market growth.
North America is projected to have the highest CAGR over the forecast period, as red yeast rice is often marketed and consumed in North America as a dietary supplement, particularly for its potential cholesterol-lowering properties. Consumers may use red yeast rice supplements as a natural alternative to traditional statin medications. Additionally, various companies in North America may produce and distribute red yeast rice supplements and competition in the market can involve factors such as product quality, brand reputation, and marketing strategies.
Key players in the market
Some of the key players in the Red Yeast Rice Market include Shanghai Fengyi Biotechnology Co., Ltd, Nutraceuticals International Group, Golden Grain Group Limited, Zhejiang Sanhe Bio-Tech Co., Ltd., Nanjing Zelang Medical Technology Co., Ltd., Wuhan Jiacheng Biotechnology Co., Ltd, Fermentek Biotechnology, Hebei Food Additive Co., Ltd., CSPC Pharmaceutical Group Limited, Alesco S.r.L., Amazing Nutrition, Giellepi SpA, Sylvan Wellness, PLAMED Green Science Group, NOW Health Group, Purelife Bioscience Co Ltd, Natural Plus and Swanson
In January 2024, NOW Sports Named Official Sports Nutrition Partner of the Brooks Beasts Track Club. The strategic alignment comes as Brooks professional athletes look to compete on the world's biggest stage at this summer's 2024 Paris Olympics
In January 2024, NOW Partners with Top Wellness Experts to Launch You're Enough NOW Campaign. Peloton instructor emma lovewell, Celebrity Health Coach Kelly LeVeque, and Functional Medicine Practitioner Dr. Will Cole Will Inspire People to Feel Fulfilled, Nourished and Strong
In July 2023, Plamed launched a speech and participated the exhibition at Ringier PCT 2023. Many big names from domestic and foreign beauty and personal care brands, raw material supplier, OEM companies, scientific research institutes, and industry associations gathered in large numbers.